Why Are Chronic Diseases Affecting Younger Populations? A New Wave of Patients Is Reshaping the Healthcare Industry

These are no longer rare occurrences.
People born after 1995 are being diagnosed with high blood pressure, while those born after 2000 are being hospitalized for gout — these are no longer unusual stories shared on social media.

Chronic diseases are affecting increasingly younger populations, and the healthcare industry has no choice but to adapt accordingly.

In the past, chronic illnesses were considered the “preserve” of middle-aged and elderly groups, something to be addressed only later in life. Today, however, they are emerging much earlier and persisting across younger stages of life. This means the healthcare industry can no longer wait until people become ill before responding; it must intervene earlier.

01.Demand Has Changed:It Is No Longer Something to “Wait Until Old Age” for — It Is Happening Now

Let us begin with a set of figures.

As of the end of 2025, China’s population aged 65 and above reached 224 million, accounting for 15.9% of the total population. In other words, one in every six people in China is now aged 65 or older. This segment of demand is inherently rigid and continues to grow.

(Source: Accenture)

But the real variable lies at the other end of the spectrum.

Among the 18–35 age group, the prevalence of hypertension has already reached 8.9%, while diabetes stands at 3.2% — effectively doubling over a five-year period. The rates of hyperlipidemia and fatty liver disease are even higher, reaching 85.5% and 52.6%, respectively. Even more strikingly, more than 96% of individuals in this group have at least one metabolic condition.

What does this mean in practical terms?

Based on this ratio, in a standard office of 50 people, there may be four to five individuals with hypertension and one to two with diabetes, while more than half may be affected by hyperlipidemia or fatty liver disease.

Chronic disease is no longer “a problem for certain groups”; it is increasingly becoming a widespread condition.

The issue is that the healthcare system has not yet fully caught up with this shift.

To be sure, progress has been made in recent years. China has established 581 national demonstration zones for chronic disease prevention and control, and according to the National Health Commission, the national health literacy rate reached 33.69% in 2025. However, compared with the pace at which demand is growing, the system is still lagging behind.

(Source: Publicity Department of the National Health Commission of the People’s Republic of China)

Instead, demand has moved first.

From 2019 to 2023, the size of China’s AI healthcare market increased from RMB 2.70 billion to RMB 10.70 billion, while its share of the broader artificial intelligence industry rose from 6.4% to 8.6%. It is projected that by 2028, the market size will further expand to RMB 97.60 billion, with its share of the AI industry increasing to 15.4%.

(Source: LeadLeo Research Institute)

Taken together, these signals point to a clear conclusion: it is not healthcare that is changing first — it is people. Demand has already moved ahead of the system.

02.Why Is This Shift Happening? It Is Not the Result of a Single Cause, but Several Factors Occurring Simultaneously

The high incidence of chronic disease among younger people cannot be attributed simply to “unhealthy lifestyles.” At a deeper level, it is the result of several factors converging at the same time.

First, there has been a fundamental shift in lifestyle patterns.

Prolonged sitting, late nights, and takeaway-based diets have moved from being occasional behaviors to becoming a normalized part of daily life. According to data from Insight Research’s proprietary industry report database, sub-health conditions among working professionals are becoming increasingly widespread. These pressures of modern life are shifting healthcare demand away from traditional “acute treatment” and toward long-term health management.

(Source: Zhaopin)

Second, there is an issue of awareness.

According to data from the National Health Commission, the proportion of the working-age population aged 18 to 44 who undergo regular health check-ups is only 31.2%, and nearly 70% of patients still do not receive standardized treatment after the onset of their condition. In many cases, people are “somewhat aware, but do not take it seriously.”

The misconception that “young people do not develop chronic diseases” remains widespread. Most individuals focus only on controlling numerical indicators while underestimating the value of non-pharmaceutical interventions such as dietary management, which further accelerates the progression of chronic diseases.

Third, there is the lag within the healthcare system itself.

Historically, the healthcare system has been designed primarily to address “problems that have already occurred,” rather than to intervene “before problems arise.” This model was highly effective in the era of acute illness, but it appears increasingly inadequate in the context of chronic disease management.

At the same time, policy changes are reinforcing this shift. The Healthy China 2030 initiative has elevated chronic disease management to a full-lifecycle priority; the family mutual-aid function under the medical insurance system now covers 320 million households; and DRG/DIP payment models have been implemented in the vast majority of hospitals. Together, these developments are steering the system toward a model focused less on treatment and more on ongoing management.

03.Trends: What Changes Are Taking Place in the Industry?

As demand changes, the industry will inevitably change with it; the only question is how quickly. Even now, several clear directions are already emerging.

First, healthcare scenarios are moving earlier in the care pathway.

Online medical consultations now account for nearly 30% of total interactions, home-use testing devices are becoming increasingly common, and the in vitro diagnostics market is expected to soon exceed RMB 50 billion. Many activities that previously took place only in hospitals are now being shifted to earlier stages of intervention.

Second, technology is redefining the boundaries of care.

AI healthcare has grown rapidly in recent years, and in certain early-screening scenarios, its accuracy has already approached or even surpassed that of human professionals. Its greatest value, however, does not lie in replacing doctors, but in enabling many health issues to be identified at a much earlier stage.

(Source: Ipsos)

Third, chronic disease is increasingly becoming a long-term business model.

The number of users of health management apps has exceeded 80 million, while chronic disease-related insurance products and health-oriented food categories are also growing. Services built around an individual’s long-term health status offer greater potential than one-time treatment alone.

Looking more deeply, the boundaries of the industry are also beginning to loosen. Healthcare is no longer confined to hospitals; insurance, food, and technology companies are all moving into the space, and even medical insurance funds are beginning to connect with commercial insurance.

Simply put, healthcare is expanding beyond the traditional model of “treating illness.”

04.Cross-Sector Collaboration:Chronic Disease Management Is Becoming a Cross-Industry Business

Chronic disease management is increasingly becoming a cross-industry business.

Insurance companies are beginning to offer policies bundled with health management services, launching commercial health insurance products related to chronic disease while also linking with the public medical insurance system. These offerings cover the full process of chronic disease screening, medication, and management, effectively integrating insurance services with healthcare services.

Food companies are developing low-purine, low-sugar, and low-fat products, while proactively collaborating with medical institutions and research organizations to create health-focused food products that better meet the needs of different population groups. This is driving a deeper integration between healthy eating and chronic disease prevention and control.

Internet platforms are making online consultations, prescription circulation, and medicine delivery part of everyday life. At the same time, technologies such as AI and the Internet of Things are being widely applied in chronic disease screening and long-term management, while frontier technologies such as brain-computer interfaces are accelerating toward practical deployment.

In the fields of research and education, investment in medical technology R&D continues to increase, with efforts focused on key areas such as the mechanisms of chronic disease onset, novel drugs, and testing technologies. At the same time, stronger efforts are being made to cultivate professional talent, including general practitioners and chronic disease management specialists. More than 12,000 new general practitioners are added annually on average, helping to drive Chinese innovative drugs and high-end medical devices onto the global stage.

05.International Comparison:What Stage Is China’s Chronic Disease Management Currently In?

Looking at the global landscape provides a clearer perspective on the current stage of chronic disease management in China.

United States: A Mature Prevention System, but at High Cost

Chronic disease management in the United States began relatively early, and the country has developed a comparatively complete system covering prevention, diagnosis and treatment, and rehabilitation. According to data from the U.S. Centers for Disease Control and Prevention (CDC), more than 60% of American adults suffer from at least one chronic disease, and 40% have two or more. In response, the United States has established a chronic disease management system led primarily by commercial insurance, using tools such as health risk assessments and disease management programs to control medical expenditures.

However, the shortcomings are also evident. Per capita healthcare expenditure in the United States is seven to eight times that of China, yet the outcomes in chronic disease control remain less than ideal. Hypertension control rates are around 50%, while diabetes control rates are approximately 60% — levels that are broadly comparable to those in China.

Japan: An Early Leader in Aging, with Community-Based Management at the Core

Japan is one of the most aged societies in the world, with more than 28% of its population aged 65 and above. Its chronic disease management system is centered on community-based care. Through the “Specific Health Checkup” system, individuals aged 40 to 74 are required to undergo annual metabolic syndrome screening, with the results linked to insurance costs.

This system has produced notable results. The prevalence of hypertension among Japanese men fell from 35% in 2000 to 28% in 2025, while among women it declined from 25% to 20%.

China: Catching Up Rapidly, but the System Is Still Under Construction

Compared with developed countries, China started later in chronic disease management, but its pace of catch-up has been rapid. Since the launch of the Healthy China strategy in 2015, chronic disease prevention and control has been elevated to an unprecedented level of importance. The establishment of 581 national demonstration zones for chronic disease prevention and control, together with a national health literacy rate of 33.69%, reflects this effort.

Yet substantial gaps remain:

The hypertension control rate is around 30%, lower than the U.S. level of 50%;
The awareness rate for diabetes is around 50%, lower than Japan’s 70%;
Primary healthcare institutions still have insufficient capacity for chronic disease management, and patients continue to crowd into large hospitals.

What does this mean?

The gap itself represents opportunity. China’s chronic disease management market still holds significant growth potential, particularly in areas such as primary healthcare, digital management, and preventive intervention.

Insight Research Institute: Where Are the Opportunities? Three Areas Worth Watching

Based on its assessment of industry trends, Insight Research Institute has identified three areas worth particular attention.

Direction One: Digital Chronic Disease Management Platforms

Traditional chronic disease management relies heavily on hospitals and physicians, but healthcare resources are limited and cannot cover the hundreds of millions of people living with chronic illnesses. Digital platforms offer a way to break through this bottleneck.

Remote monitoring: data from home-use devices such as blood pressure monitors and blood glucose meters can be uploaded in real time, enabling doctors to track patients’ conditions remotely;
AI-assisted decision-making: AI systems based on big data can identify high-risk groups and support earlier intervention;
Patient education: apps and mini-programs can be used to deliver scientific knowledge to patients and improve treatment adherence.

Representative companies in this segment include Ping An Good Doctor, WeDoctor, and Chunyu Doctor, although the sector as a whole is still at an early stage and its business models remain to be fully validated.

Direction Two: Chronic Disease-Friendly Consumer Products

The everyday needs of people with chronic diseases are giving rise to new categories of consumer products.

Low-sugar foods: the market for sugar-free beverages and low-GI foods is growing rapidly;
Functional foods: products that help lower blood pressure or lipid levels are gaining popularity;
Home-use medical devices: products such as blood pressure monitors, blood glucose meters, and oxygen concentrators are increasingly entering households.

The defining characteristic of this segment is its relatively low entry barrier, but success depends on building professional credibility through cooperation with medical institutions.

(Source: Liandanlu Big Data)

Direction Three: Innovation in Commercial Health Insurance

Basic medical insurance coverage remains limited, and commercial health insurance can serve as an important supplement.

Dedicated insurance products for chronic diseases: insurance products specifically designed for patients with conditions such as hypertension and diabetes;
Coverage for individuals with pre-existing conditions: breaking through the traditional restriction that only healthy individuals are eligible for insurance;
Insurance + services: bundling insurance with health management services to improve user retention.

The challenge in this segment lies in the lack of sufficient actuarial data and the high difficulty of risk control, but the market potential is substantial.

As chronic diseases affect younger populations and the pace of aging accelerates, the convergence of these two trends is forcing the healthcare industry to change.

From treating illness to preventing it, from hospitals to everyday life, and from one-time treatment to long-term management — this transformation has only just begun.

For industry participants, the opportunity lies in who can identify these shifts earlier and respond more effectively to these “forward-shifted” demands. For ordinary people, it means that future health management will become more convenient, more personalized, and more proactive.

The younger onset of chronic disease is not alarmist rhetoric; it is a reality already unfolding. The healthcare industry’s response has only just entered its first chapter.